<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884155</url>
  </required_header>
  <id_info>
    <org_study_id>UCBStroke</org_study_id>
    <nct_id>NCT01884155</nct_id>
  </id_info>
  <brief_title>Allogeneic Umbilical Cord Blood Therapy for Stroke</brief_title>
  <official_title>Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Patients With Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MinYoung Kim, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bundang CHA Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label trial is conducted to investigate the efficacy and safety of allogeneic
      umbilical cord blood (UCB) therapy for patients with stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is one of the most common etiologies causing disability in developed countries. There
      remains no proven treatments except tissue plasminogen activator currently. Based on
      promising results of cell therapy in animal stroke models, efforts to apply cell therapy for
      patients with stroke has been made. UCB possess various stem or progenitor cells and is known
      to secrete neurotrophic factors to repair injured brain. This clinical research aims to
      determine the safety and efficacy of allogeneic UCB for stroke.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>allogeneic cord blood for stroke patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Balance</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Mobility</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Muscle strength and Spasticity</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Activities of Daily Living</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Function of Upper extremity</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hand function</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual perception</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cognition</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Language</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sensory function</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Brain structure</measure>
    <time_frame>Baseline - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Brain glucose metabolism</measure>
    <time_frame>Baseline - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Neural activity</measure>
    <time_frame>Baseline - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring Adverse Events</measure>
    <time_frame>Baseline - 1 month - 3 months - 6 months - 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Allogeneic umbilical cord blood therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic umbilical cord blood therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic umbilical cord blood therapy</intervention_name>
    <arm_group_label>Allogeneic umbilical cord blood therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic or hemorrhagic stroke

          -  Onset duration over 12 months

          -  Hemisphere lesions except brain stem and cerebellar lesions

          -  National Institute Health Stroke Scale: 10 to 15

        Exclusion Criteria:

          -  Possibility of hypersensitivity drugs used in this study

          -  Uncontrolled hypertension or cardiovascualr diseases

          -  Malignant cancer

          -  Renal or hepatic dysfunction (Consultation to specialist in nephrology or
             gastroenterology in case of renal or hepatic dysfunction)

          -  Severe pulmonary dysfunction

          -  Traumatic brain injury

          -  Lack of matched UCB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MinYoung Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2013</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bundang CHA Hospital</investigator_affiliation>
    <investigator_full_name>MinYoung Kim, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

